Ironwood Pharmaceuticals Income Statement (2009-2026) | IRWD

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	104.03M	103.75M	117.13M	97.53M	97.23M	108.64M	107.20M	104.06M	107.38M	113.74M	117.55M	74.88M	94.40M	91.59M	90.55M	41.14M	85.24M	122.06M	47.71M	106.51M
Cost of Revenue (Quarter)
Gross Profit (Quarter)
Operating items
Amortization - Intangibles (Quarter)
Research & Development (Quarter)	12.16M	10.91M	31.85M	10.82M	11.45M	11.54M	10.45M	12.85M	6.00M	32.98M	35.68M	25.82M	30.39M	29.83M	25.39M	27.43M	23.37M	22.47M	21.86M	21.94M
Selling, General & Administrative (Quarter)	27.05M	27.74M	28.69M	28.86M	30.12M	28.62M	28.39M	31.12M	52.48M	36.05M	38.67M	37.60M	36.96M	36.11M	33.59M	24.26M	16.80M	21.91M	19.29M	12.03M
Restructuring Costs (Quarter)	-0.28M	-0.07M
Other Operating Expenses (Quarter)									1,132.04M	4.68M	5.62M	0.44M	2.07M	0.02M	0.07M	18.56M	-0.25M	2.20M	-0.25M	-0.04M
Operating Expenses (Quarter)	38.93M	38.58M	60.54M	39.68M	41.58M	40.16M	38.84M	43.96M	1,190.52M	73.72M	79.96M	63.86M	69.42M	65.96M	59.05M	70.25M	39.92M	46.58M	40.90M	33.93M
Operating Income (Quarter)	65.10M	65.17M	-133.53M	57.85M	55.66M	68.47M	-128.97M	60.10M	-1083.14M	40.02M	37.59M	11.02M	24.98M	25.64M	31.49M	-29.11M	45.32M	75.48M	-76.99M	72.57M
EBIT (Quarter)	65.10M	65.17M	-133.53M	57.85M	55.66M	68.47M	-128.97M	60.10M	-1083.14M	40.02M	37.59M	11.02M	24.98M	25.64M	31.49M	-29.11M	45.32M	75.48M	-76.99M	72.57M
Non-operating items
Non Operating Investment Income (Quarter)	-3.17M	2.16M	-2.57M	0.73M	-0.68M	0.15M	-0.02M	0.02M
Interest & Investment Income (Quarter)	0.17M	0.18M	0.18M	0.23M	1.02M	2.81M	5.45M	7.27M	8.76M	1.75M	1.19M	1.17M	1.37M	1.15M	0.78M	0.87M	0.82M	0.93M	1.46M	1.70M
Other Non Operating Income (Quarter)																0.04M	0.04M	0.04M	0.08M	0.04M
Non Operating Income (Quarter)	-10.73M	-5.50M	-10.34M	-1.38M	-1.87M	1.43M	3.90M	5.76M	6.92M	-8.09M	-7.23M	-6.06M	-6.10M	-8.27M	-7.50M	0.04M	-7.50M	-7.46M	-6.35M	-7.40M
Net income details
EBT (Quarter)	54.37M	59.67M	46.26M	56.47M	53.78M	69.91M	72.27M	65.86M	-1076.22M	31.93M	-196.17M	4.96M	18.88M	17.37M	-143.10M	-36.27M	37.82M	68.02M	-160.70M	65.17M
Tax Provisions (Quarter)	-336.93M	3.80M	4.87M	17.70M	16.70M	19.59M	23.40M	20.15M	13.30M	18.00M	32.10M	9.12M	19.70M	13.70M	-46.33M	1.10M	14.20M	27.94M	-38.07M	24.40M
Profit After Tax (Quarter)	391.30M	55.84M	41.37M	38.80M	37.08M	50.32M	48.87M	45.71M	-1062.19M	15.32M	-1.09M	-4.16M	-0.86M	3.65M	2.26M	-37.39M	23.60M	40.08M	-2.28M	40.77M
Income from Non-Controlling Interests (Quarter)									-27.29M	-1.37M	-0.66M
Income from Continuing Operations (Quarter)	391.30M	55.87M	41.38M	38.77M	37.08M	50.32M	48.87M	45.71M	-1089.52M	13.93M	-228.28M	-4.16M	-0.82M	3.67M	-96.76M	-37.37M	23.62M	40.08M	-122.63M	40.77M
Consolidated Net Income (Quarter)	391.30M	55.87M	41.38M	38.77M	37.08M	50.32M	48.87M	45.71M	-1089.52M	13.93M	-228.28M	-4.16M	-0.82M	3.67M	-96.76M	-37.37M	23.62M	40.08M	-122.63M	40.77M
Income towards Parent Company (Quarter)	391.30M	55.87M	41.38M	38.77M	37.08M	50.32M	48.87M	45.71M	-1089.52M	13.93M	-228.28M	-4.16M	-0.82M	3.67M	-96.76M	-37.37M	23.62M	40.08M	-122.63M	40.77M
Net Income towards Common Stockholders (Quarter)	391.30M	55.87M	41.38M	38.77M	37.08M	50.32M	48.87M	45.71M	-1089.52M	13.93M	-228.28M	-4.16M	-0.82M	3.67M	-96.76M	-37.37M	23.62M	40.08M	-122.63M	40.77M
Additional items
EPS (Basic) (Quarter)	2.42	0.34	0.25	0.25	0.24	0.33	0.32	0.30	-6.84	0.10	-0.01	-0.03	-0.01	0.02	0.01	-0.23	0.15	0.25	-0.01	0.25
EPS (Weighted Average and Diluted) (Quarter)	2.39	0.34	0.25	0.21	0.21	0.28	0.27	0.25	-6.84	0.09	-0.01	-0.03	-0.01	0.02	0.01	-0.23	0.14	0.23	-0.01	0.24
Shares Outstanding (Weighted Average) (Quarter)	161.95M	162.74M	162.25M	157.82M	155.55M	154.71M	154.37M	154.45M	155.37M	155.89M	155.44M	157.70M	159.01M	159.71M	159.08M	160.97M	161.35M	161.64M	161.84M	163.45M
Shares Outstanding (Diluted Average) (Quarter)									154.91M			157.70M	159.01M			160.97M
EBITDA (Quarter)	391.30M	55.84M	41.37M	38.80M	37.08M	50.32M	48.87M	45.71M	-1062.19M	40.02M	37.59M	11.02M	24.98M	25.64M	31.49M	-29.11M	45.32M	75.48M	-76.99M	72.57M
Interest Expenses (Quarter)	7.73M	7.84M	7.95M	2.34M	2.21M	1.52M	1.53M	1.53M	1.84M	9.84M	8.42M	7.23M	7.47M	9.42M	8.91M	8.07M	8.36M	8.43M	7.89M	9.14M
Tax Rate (Quarter)	-619.68%	6.37%	10.53%	31.35%	31.06%	28.02%	32.38%	30.59%	-1.24%	56.37%	-16.37%	183.95%	104.37%	78.88%	32.38%	-3.03%	37.54%	41.08%	23.69%	37.44%

Research Tools

Ironwood Pharmaceuticals Income Statement (2009-2026) | IRWD

Create an account

Sign In

Reset Password